Over the past decade, the Novartis Malaria Initiative has become one of the largest access-to-medicine programs in the healthcare industry, measured by the number of patients reached. Our holistic approach enables us to offer solutions that go “beyond the pill” and drive improved patient outcomes.
Since 2001, working with a range of organizations, we have provided more than 800 million treatments for adults and children, without profit, to more than 60 malaria-endemic countries, contributing to a significant reduction of the death toll from malaria, mostly infants and children.
The Novartis Malaria Initiative is built on four key pillars – treatment, access, capacity building, and research and development. Innovation and partnerships underpin everything we do. Beyond discovering next-generation treatments, a key focus of our work is to find creative ways to expand access to medicines through alliances between industry, governments and non-governmental organizations.
Novartis has been at the forefront of a change in the treatment of malaria.